[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100172689":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":10,"locations":22,"responsibleParty":42,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Breast Cancer",null,[12],"Other: Breast Cancer-Related Lymphedema Screening",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Breast Cancer-Related Lymphedema Screening","All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.",[9],[19],{"name":20,"affiliation":5,"role":21},"Alphonse G Taghian, MD PhD","PRINCIPAL_INVESTIGATOR",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Boston","Massachusetts","02134","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-71.05977,42.35843,{"lat":34,"lon":33},[37,41],{"name":20,"role":38,"phone":39,"phoneExt":10,"email":40},"CONTACT","617-726-6050","ataghian@partners.org",{"name":20,"role":21,"phone":10,"phoneExt":10,"email":10},{"type":21,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Alphonse Taghian","Chief of Breast Service",[46],{"name":47,"class":48},"National Cancer Institute (NCI)","NIH","100172689","prospective-screening-for-breast-cancer-related-lymphedema-100172689",false,"NCT01521741","Prospective Screening for Breast Cancer-related Lymphedema","Prospective Screening for Breast Cancer-related Lymphedema: Analysis of Objective Measurements, Symptoms, Functionality, and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer.","Inclusion Criteria:\n\n* Confirmed diagnosis of breast cancer\n* Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid)\n\nExclusion Criteria:\n\n* Evidence of distant metastatic disease that may cause edema,\n* Previous breast cancer\n* History of lymphedema\n* Pregnancy at the time of accrual and\u002For cardiac implants (contraindications for BIS)\n* Medical conditions that cause fluid retention or swelling (e.g. axillary cancer recurrence, renal insufficiency, congestive heart failure).","FEMALE","18 Years",{"count":59,"type":60},10000,"ESTIMATED","OBSERVATIONAL","The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and\u002For trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening.",[64],"Lymphedema",[9,64,66,67],"Symptoms","Screening","2025-12-23",{"date":70,"type":71},"2025-12-24","ACTUAL",{"date":73,"type":10},"2009-08",{"date":75,"type":60},"2026-12",{"name":5,"class":6},1]